NCT03647488View on ClinicalTrials.gov

Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 26, 2018

Primary Completion Date

September 7, 2020

Study Completion Date

September 7, 2020

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Capmatinib

Capmatinib 400 mg (tablets) orally taken twice daily

DRUG

Spartalizumab

Spartalizumab 400 mg via intravenous infusion once every 28 days

DRUG

Docetaxel

Docetaxel 75mg/m2 i.v. following local guidelines as per standard of care and product labels once every 21 days

Trial Locations (8)

3000

Novartis Investigative Site, Leuven

28009

Novartis Investigative Site, Madrid

38043

Novartis Investigative Site, Grenoble

50937

Novartis Investigative Site, Cologne

59037

Novartis Investigative Site, Lille Cédex

72703

Highlands Oncology Group, Fayetteville

6423906

Novartis Investigative Site, Tel Aviv

08036

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY